Emerging biotechnological strategies for non-viral antiangiogenic gene therapy
Emerging biotechnological strategies for non-viral antiangiogenic gene therapy
复制标题
非病毒抗血管生成基因治疗的新兴生物技术策略
DOI：
10.1007/s10456-012-9295-8
复制
发表时间：
2012-08
期刊：
影响因子：
9.8
通讯作者：
Zhang Na
中科院分区：
文献类型：
--
作者：
Liu Chunxi;Zhang Na
血管生成已经成为癌症治疗的一个有前途的靶点。随着生物技术的发展，近20年来，针对肿瘤血管生成的有效治疗方法的研究取得了重大进展。基因治疗由于在患者细胞内表达持续水平的治疗剂的能力而引起了相当大的兴趣。然而，基因治疗的主要挑战是将治疗基因有效递送到靶位点。与病毒策略相比，非病毒策略因其广泛认可的安全性和较低的副作用而更容易被接受。本文综述了血管生成的基础生物学、抗血管生成基因治疗的潜在优势、通过生物技术开发的治疗性基因药物以及以更可控的方式增强非病毒基因治疗靶向肿瘤血管生成的生物技术策略，重点介绍了RNA干扰、配体导向血管靶向策略、血管内皮生长因子途径和肿瘤相关巨噬细胞靶向。总之，抗血管生成基因治疗在推进癌症治疗方面具有很大的前景。开发更好的非病毒生物技术平台将有利于抗血管生成的靶向肿瘤基因治疗方法，支持其在人体临床试验中的评估，并在不久的将来实现实际应用。
Angiogenesis has emerged as a promising target of cancer treatment. With the development of biotechnology, major progress has been made in the exploring effective therapies on targeting tumor angiogenesis over the last 20 years. Gene therapy has attracted considerable interest by virtue of the capabilities of expressing sustained levels of therapeutic agents within cells of the patients. However, the major challenge of gene therapy is the efficient delivery of therapeutic gene to the target site. Compared with viral strategies, non-viral strategies were more acceptable by their widely recognized security and lower side effects. This paper reviews the basic biology of angiogenesis, the potential advantages of antiangiogenic gene therapy, the therapeutic genetic drugs developed through biotechnology, as well as the biotechnological strategies that enhancing non-viral gene therapy targeting to tumor angiogenesis in a more controlled manner, with great respect to RNA interference, ligand-directed vascular targeting strategies, vascular endothelial growth factor pathway and tumor associated macrophages targeting. In conclusion, antiangiogenic gene therapy holds great promise in advancing cancer therapy. Developing better non-viral biotechnological platforms will benefit antiangiogenic targeted cancer gene therapeutic methods, support their evaluation in human clinical trials and realize the actual utilization in the near future.
登录
查看更多内容
影响因子：
4.9
作者：
Ko YT;Falcao C;Torchilin VP
通讯作者：
Torchilin VP
影响因子：
3.5
作者：
Ghaedi, Mahboobe;Soleimani, Masoud;Wu, Jian
通讯作者：
Wu, Jian
DOI：
--
发表时间：
2009
期刊：
--
影响因子：
--
作者：
Siyu Cao;A. Cripps;Ming QWei
通讯作者：
Siyu Cao;A. Cripps;Ming QWei
影响因子：
--
作者：
Mross K;Frost A;Scheulen ME;Krauss J;Strumberg D;Schultheiss B;Fasol U;Büchert M;Krätzschmer J;Delesen H;Rajagopalan P;Christensen O
通讯作者：
Christensen O
影响因子：
--
作者：
Ambasta RK;Sharma A;Kumar P
通讯作者：
Kumar P